FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282916169> ?p ?o ?g. }

• W4282916169 endingPage "5874" @default.
• W4282916169 startingPage "5874" @default.
• W4282916169 abstract "Abstract Diversity in Human Leukocyte Antigen (HLA) genes has been associated with risk of several diseases, including Non-Hodgkin’s lymphoma and ulcerative colitis. Reduced diversity at HLA loci may adversely affect the host’s ability to recognize foreign antigens and tumor neoantigens, and subsequently, increase disease burden. To better understand the role of inherited HLA diversity in colorectal cancer (CRC) risk, we utilized data from a population-based study of 10,347 participants (5,574 CRC cases and 4,773 healthy controls) from the Molecular Epidemiology of Colorectal Cancer Study (MECC). Germline DNA samples were genotyped using genome-wide arrays, and HLA Class I and II four-digit resolution alleles were imputed using SNP2HLA and a reference panel of 5,225 individuals from the Type 1 Diabetes Genetics Consortium. Heterozygosity and homozygosity at each HLA locus and the number of homozygous genotypes at class I loci (A, B, C) and class II loci (DQB1, DRB1, DPB1) were quantified. To examine the joint effect of Class I and Class II loci, we combined the total number of homozygotes for all loci and categorized into 3 groups: heterozygotes at all loci, 1 to 4 homozygotes, or 5 or more homozygotes. Logistic regression was used to estimate the risk of CRC associated with HLA locus homozygosity. Individuals with heterozygous genotypes for all loci served as the reference category, and analyses were adjusted for sex, age, genotyping platform, and global ancestry. Individuals with homozygous genotypes at all 3 Class I genes had an increased risk of CRC when compared to those with heterozygous genotypes at all Class I loci (OR: 1.34; 95% CI: 1.02-1.76, P = 0.033; Ptrend = 0.039). A similar association was observed for Class II loci, with an OR of 1.32 (95% CI: 1.05-1.65, P = 0.015; Ptrend = 0.157). For HLA Class I and II combined, individuals with five or more homozygous genotypes at HLA class I or II loci were at higher risk for developing CRC (OR: 1.84, 95% CI: 1.24-2.73, P = 0.0023; Ptrend = 0.015), when compared to those with all heterozygous genotypes. Our findings support a heterozygote advantage at HLA class I and II loci as a protective factor for CRC. This indicates an important role for HLA genetic variability in the etiology of CRC potentially operating through a mechanism of decreased diversity of tumor neoantigens that can be displayed to the adaptive immune system. Citation Format: Ya-Yu Tsai, Chenxu Qu, Joseph D. Bonner, Rebeca Sanz-Pamplona, Sidney Lindsey, Marilena Melas, Kevin J. McDonnell, Gregory E. Idos, Christopher P. Walker, Kevin K. Tsang, Diane M. Da Silva, Ferran Moratalla, Asaf Maoz, Hedy S. Rennert, W. Martin Kast, Joel K. Greenson, Victor Moreno, Gad Rennert, Stephen B. Gruber, Stephanie L. Schmit. Heterozygote advantage at HLA class I and II loci and colorectal cancer risk [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5874." @default.
• W4282916169 created "2022-06-16" @default.
• W4282916169 creator A5008391345 @default.
• W4282916169 creator A5013284308 @default.
• W4282916169 creator A5029862175 @default.
• W4282916169 creator A5031285917 @default.
• W4282916169 creator A5031398136 @default.
• W4282916169 creator A5042231024 @default.
• W4282916169 creator A5044013471 @default.
• W4282916169 creator A5045707052 @default.
• W4282916169 creator A5048013245 @default.
• W4282916169 creator A5048825007 @default.
• W4282916169 creator A5051463129 @default.
• W4282916169 creator A5064805248 @default.
• W4282916169 creator A5066518394 @default.
• W4282916169 creator A5070083610 @default.
• W4282916169 creator A5070703103 @default.
• W4282916169 creator A5072875338 @default.
• W4282916169 creator A5073146927 @default.
• W4282916169 creator A5081037579 @default.
• W4282916169 creator A5085891308 @default.
• W4282916169 date "2022-06-15" @default.
• W4282916169 modified "2023-10-07" @default.
• W4282916169 title "Abstract 5874: Heterozygote advantage at HLA class I and II loci and colorectal cancer risk" @default.
• W4282916169 doi "https://doi.org/10.1158/1538-7445.am2022-5874" @default.
• W4282916169 hasPublicationYear "2022" @default.
• W4282916169 type Work @default.
• W4282916169 citedByCount "0" @default.
• W4282916169 crossrefType "journal-article" @default.
• W4282916169 hasAuthorship W4282916169A5008391345 @default.
• W4282916169 hasAuthorship W4282916169A5013284308 @default.
• W4282916169 hasAuthorship W4282916169A5029862175 @default.
• W4282916169 hasAuthorship W4282916169A5031285917 @default.
• W4282916169 hasAuthorship W4282916169A5031398136 @default.
• W4282916169 hasAuthorship W4282916169A5042231024 @default.
• W4282916169 hasAuthorship W4282916169A5044013471 @default.
• W4282916169 hasAuthorship W4282916169A5045707052 @default.
• W4282916169 hasAuthorship W4282916169A5048013245 @default.
• W4282916169 hasAuthorship W4282916169A5048825007 @default.
• W4282916169 hasAuthorship W4282916169A5051463129 @default.
• W4282916169 hasAuthorship W4282916169A5064805248 @default.
• W4282916169 hasAuthorship W4282916169A5066518394 @default.
• W4282916169 hasAuthorship W4282916169A5070083610 @default.
• W4282916169 hasAuthorship W4282916169A5070703103 @default.
• W4282916169 hasAuthorship W4282916169A5072875338 @default.
• W4282916169 hasAuthorship W4282916169A5073146927 @default.
• W4282916169 hasAuthorship W4282916169A5081037579 @default.
• W4282916169 hasAuthorship W4282916169A5085891308 @default.
• W4282916169 hasConcept C104317684 @default.
• W4282916169 hasConcept C106208931 @default.
• W4282916169 hasConcept C121608353 @default.
• W4282916169 hasConcept C135763542 @default.
• W4282916169 hasConcept C143589142 @default.
• W4282916169 hasConcept C147483822 @default.
• W4282916169 hasConcept C153209595 @default.
• W4282916169 hasConcept C180754005 @default.
• W4282916169 hasConcept C188280979 @default.
• W4282916169 hasConcept C31467283 @default.
• W4282916169 hasConcept C526805850 @default.
• W4282916169 hasConcept C54355233 @default.
• W4282916169 hasConcept C84597430 @default.
• W4282916169 hasConcept C86803240 @default.
• W4282916169 hasConceptScore W4282916169C104317684 @default.
• W4282916169 hasConceptScore W4282916169C106208931 @default.
• W4282916169 hasConceptScore W4282916169C121608353 @default.
• W4282916169 hasConceptScore W4282916169C135763542 @default.
• W4282916169 hasConceptScore W4282916169C143589142 @default.
• W4282916169 hasConceptScore W4282916169C147483822 @default.
• W4282916169 hasConceptScore W4282916169C153209595 @default.
• W4282916169 hasConceptScore W4282916169C180754005 @default.
• W4282916169 hasConceptScore W4282916169C188280979 @default.
• W4282916169 hasConceptScore W4282916169C31467283 @default.
• W4282916169 hasConceptScore W4282916169C526805850 @default.
• W4282916169 hasConceptScore W4282916169C54355233 @default.
• W4282916169 hasConceptScore W4282916169C84597430 @default.
• W4282916169 hasConceptScore W4282916169C86803240 @default.
• W4282916169 hasIssue "12_Supplement" @default.
• W4282916169 hasLocation W42829161691 @default.
• W4282916169 hasOpenAccess W4282916169 @default.
• W4282916169 hasPrimaryLocation W42829161691 @default.
• W4282916169 hasRelatedWork W1965726430 @default.
• W4282916169 hasRelatedWork W1983574409 @default.
• W4282916169 hasRelatedWork W1993755972 @default.
• W4282916169 hasRelatedWork W1995257130 @default.
• W4282916169 hasRelatedWork W2027506631 @default.
• W4282916169 hasRelatedWork W2131839889 @default.
• W4282916169 hasRelatedWork W2157891295 @default.
• W4282916169 hasRelatedWork W2163650164 @default.
• W4282916169 hasRelatedWork W2384927114 @default.
• W4282916169 hasRelatedWork W2414907829 @default.
• W4282916169 hasVolume "82" @default.
• W4282916169 isParatext "false" @default.
• W4282916169 isRetracted "false" @default.
• W4282916169 workType "article" @default.